Company news
Oncolytics Biotech Inc. news in 2021
Oncolytics Biotech Inc.'s news releases, calls and decks from 2021, newest first.
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
December 21, 2021
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
December 15, 2021
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
November 19, 2021
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
November 5, 2021
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
November 3, 2021
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
October 19, 2021
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
October 14, 2021
Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy
September 19, 2021
Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
August 6, 2021
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
August 6, 2021
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
July 22, 2021
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
June 30, 2021
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
May 20, 2021
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
May 13, 2021
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
May 7, 2021
Oncolytics Biotech® Announces Annual General Meeting
April 30, 2021
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
April 29, 2021
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
April 12, 2021
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
April 12, 2021
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
April 8, 2021
Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors
April 5, 2021
Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting
March 10, 2021
Oncolytics Biotech® Establishes New At-The-Market Facility
March 5, 2021
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 5, 2021
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
February 26, 2021
Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors
February 23, 2021